ALKEM LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,875 INR | +1.34% |
|
-8.76% | -6.40% |
| 30/05 | Alkem Laboratories' Consolidated Profit Soars in Fiscal Q4; Shares Slump 6% | MT |
| 30/05 | Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,200 From INR4,470, Keeps at Underperform | MT |
| Sales 2024 | 127B 1.52B | Sales 2025 * | 139B 1.68B | Capitalization | 575B 6.92B |
|---|---|---|---|---|---|
| Net income 2024 | 17.96B 216M | Net income 2025 * | 21.27B 256M | EV / Sales 2024 | 4.66 x |
| Net cash position 2024 * | 18.65B 224M | Net cash position 2025 * | 29.27B 352M | EV / Sales 2025 * | 3.92 x |
| P/E ratio 2024 |
32.9
x | P/E ratio 2025 * |
27.1
x | Employees | 16,871 |
| Yield 2024 * |
0.92% | Yield 2025 * |
0.96% | Free-Float | 28.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkem Laboratories Limited
More recommendations
More press releases
| 1 day | +1.23% | ||
| 1 week | -8.76% | ||
| Current month | +1.23% | ||
| 1 month | -0.70% | ||
| 3 months | -4.98% | ||
| 6 months | +5.56% | ||
| Current year | -6.40% |
1 week
4 794.10
5 382.90
1 month
4 794.105 578.80
Current year
4 567.055 578.80
1 year
3 307.205 578.80
3 years
2 828.005 578.80
5 years
1 660.005 578.80
10 years
1 152.505 578.80
| Managers | Title | Age | Since |
|---|---|---|---|
Vikas Gupta
CEO | Chief Executive Officer | - | 22/23/22 |
Nitin Agrawal
DFI | Director of Finance/CFO | - | 01/02 |
Manish Narang
CMP | Compliance Officer | 54 | 01/06/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 84 | 08/73/08 | |
Sandeep Singh
BRD | Director/Board Member | 41 | 09/13/09 |
| Director/Board Member | 61 | 01/88/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 6 M€ | +6.07% | - | |
| 0.01% | 32 M€ | +6.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 4,875 | +1.34% | 11 970 |
| 31/24/31 | 4,810 | -2.76% | 649,815 |
| 30/24/30 | 4,947 | -6.00% | 1,490,557 |
| 29/24/29 | 5,262 | -0.97% | 495,913 |
| 28/24/28 | 5,314 | -0.44% | 216,749 |
Delayed Quote NSE India S.E., June 03, 2024 at 09:19 am IST
More quotes
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
Sector
Pharmaceuticals
Calendar
04/06/2024
- Investor Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
4,810
INR
Average target price
5,152
INR
Spread / Average Target
+7.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.40% | 6.89B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- ALKEM Stock
